Company Overview
Snapshot
Founded in August 2013 by Santiago Ini, GlaucoPharm operated with 1–10 employees. The company secured seed funding in one round from Abital and Office of the Chief Scientist in October 2014. GlaucoPharm ceased operations in April 2019.
Business overview
GlaucoPharm is a pharmaceutical company focused on developing topical treatments for glaucoma. Its core product, TG-46, targets the pyrimidinergic receptor P2Y6, which is involved in draining aqueous humor in the eye. This novel mechanism of action aims to reduce intraocular pressure by up to 45%, offering a potential alternative to existing first-line drugs. The company operates within the Pharmaceuticals sector, specifically in Drugs Discovery & Development, targeting the Healthcare & Life Sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is GlaucoPharm's primary product?
- GlaucoPharm's primary product is TG-46, a topical treatment developed for glaucoma. It targets the pyrimidinergic receptor P2Y6 to reduce intraocular pressure.
- When was GlaucoPharm founded?
- GlaucoPharm was founded in August 2013.
- Who is a founder of GlaucoPharm?
- Santiago Ini is a founder of GlaucoPharm.
- When did GlaucoPharm cease operations?
- GlaucoPharm ceased to operate in April 2019.
- Which investors participated in GlaucoPharm's seed funding round?
- In October 2014, GlaucoPharm received seed funding from Abital and Office of the Chief Scientist.